Medigrowth backs National Pain Week 2026 as gold sponsor

Medigrowth will sponsor Chronic Pain Australia’s National Pain Week from 26-31 July 2026, backing a campaign focused on the 5.4 million Australians living with chronic pain. The partnership includes new educational video content and comes as survey data show rising interest in medicinal cannabis for pain management.

Why it matters: - The sponsorship ties a medicinal cannabis biotech to one of Australia’s main chronic pain awareness campaigns. - Chronic Pain Australia says the partnership is meant to reduce stigma, improve access to reliable information and support safer care decisions with qualified health professionals. - National Pain Week reaches a large patient group, including Australians who are looking for new pain-management options.

What happened: - Medigrowth has been announced as Gold Sponsor of National Pain Week 2026. - National Pain Week runs from 26 to 31 July 2026. - Chronic Pain Australia says the campaign supports the 5.4 million Australians living with chronic pain. - Medigrowth will also be named Gold Sponsor of the 2026 National Pain Report. - The partnership is built around patient-centred research, balanced education and awareness activities.

The details: - Medigrowth produced a five-part video series for the campaign. - The videos answer common questions about medicinal cannabis, including: - “What’s the Deal with Medicinal Cannabis?” - “What Does Medicinal Cannabis Feel Like?” - “Will People Know I’ve Tried Medicinal Cannabis?” - “Will Medicinal Cannabis Work for Me?” - “Will Medicinal Cannabis Get Me High?” - Medigrowth also produced a longer interview titled “Pain Lives in Women’s Health.” - In that interview, Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis discuss healthcare leadership and Ellis’s endometriosis journey. - Chronic Pain Australia says the National Pain Survey is the longest-running survey documenting Australians’ chronic pain experiences. - The past three National Pain Reports show a growing role for medicinal cannabis in pain management. - In 2025, 31% of respondents had accessed medicinal cannabis for pain management, up from 28% in 2024. - Another 27.5% said they would like to or intend to try medicinal cannabis. - That means more than half of respondents either use or are interested in medicinal cannabis as a treatment option. - Over the same period, the barriers people report — cost and driving restrictions — each eased slightly year over year. - Medigrowth’s work includes clinical research, cannabinoid therapeutics for the Australian market and support through its digital health platform, Azure Health. - The company says its focus includes women’s health, paediatric populations and chronic pain. - Medigrowth cites a randomized, double-blind, placebo-controlled trial with Deakin University and Swinburne University on CBD in children and families living with autism. - Medigrowth also cites the EMPOWER Project, a prospective, HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia is a non-profit, non-government organisation founded in 2001. - The group says it is the national voice for 3.6 million Australians living with chronic pain. - Chronic Pain Australia also runs PainLink support services and peer-led Pain Support Groups. - More information is available at Medigrowth Australia and Chronic Pain Australia.

Between the lines: - The campaign gives Medigrowth a public-facing platform to normalize discussion of medicinal cannabis in chronic pain care. - The survey data suggest patient interest is rising faster than some of the practical barriers that have limited use. - Chronic Pain Australia is using sponsor support to expand reach while continuing to push for chronic pain to be recognized as a National Health Priority Area.

What's next: - Medigrowth’s video series and interview will roll out during National Pain Week. - Chronic Pain Australia will use the week to amplify patient voices and promote its 2026 National Pain Report. - The partnership is expected to keep medicinal cannabis in the broader national conversation about chronic pain treatment.